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A B ST R AC T  
 
Behcet’s disease is a rheumatic disease with oral aphthae, genital aphthae, arthritis and vasculitis. 
Studies about its pathogenesis have increased and is thought to be one of the autoinflammatory 
diseases in recent years. Autoinflammatory diseases occurs via excess response of innate immune 
system. In this article pathogenesis and classification of autoinflammatory diseases will be 
summarized and Behcet’s disease will be reviewed by autoinflammatory prospects.  
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Introduction 
Autoinflammatory diseases are episodic 
conditions that occur via excess response of 
innate immune system and cause fever and 
inflammation in many organs. Awareness of 
autoinflammatory diseases rose after definition 
of tumor necrosis receptor associated periodic 
syndrome (TRAPS) in 1999 by McDermott [1]. 
Advances in recognition of these diseases were 
developed in recent 20 years by increased 
awareness of this kind of conditions and by 
advances in genetic science. Treatment of these 
disease was advanced by therapies which target 
innate immune system. Autoinflammation is 
predominant in the pathogenesis of these 
conditions and may be together with 
autoimmunity. Autoinflammation is different 
from autoimmunity by which the innate 
immune system is responsible from 
autoinflammation where B lymphocyte and 
other acquired immune system cells and 
cytokines are active in the latter. Therefore, 
disease specific antibody develops and be 
detected in autoimmunity, however, neither 
antibodies related to organ damage nor antigen 
specific t lymphocytes were detectable in 
autoinflammation [2]. Figure 1 shows these 
conditions and their pathogenesis.  
Familial Mediterranean Fever (FMF) is the first 
autoinflammatory disease which was 
associated with genetics. Following this 
development, TNFRSF1 gene mutation was 
determined in TRAPS. Clinical findings of both 
diseases include episodic sterile inflammation, 
fever, myositis, arthralgia, rash-like rashes on 
the skin and serositis. The absence of any 
autoantibody and auto-reactive T cell positivity 
has led clinical research to focus on   the innate  
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immune system and possibly related gene 
studies [3]. In present study, pathogenesis and 
classification of autoinflammatory diseases will 
be summarized and Behcet’s disease will be 
reviewed by autoinflammatory prospects.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pathogenesis of autoinflammatory diseases 
The innate immune system is responsible of the 
first and fastest response to inflammation. This 
response is not antigen specific but consists of 
several cells and cytokines. The first cytokines 
Figure 1. The spectrum of autoinflammatory diseases, FMF: Familial Mediterranean fever; TRAPS: Tumor necrosis 
factor receptor associated periodic syndrome; CAPS: Cryopyrin-associated periodic syndrome; HIDS: 
Hyperimmunoglobulin D Syndrome; PAPA: Pyogenic arthritis, pyoderma gangrenosum, acne; DIRA: Deficiency of the 
interleukin-1–receptor antagonist; PAAND: Pyrin associated autoinflammation with neutrophilic dermatosis; PRAAS: 
Proteasome-associated autoinflammatory syndromes; AOSD: Adult’s still syndrome; R.A: Rheumatoid arthritis; ALPS: 
Autoimmune  lymphoproliferative syndrome; APS-1: autoimmune polyendocrine syndrome type 1 of APECED 
(autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy); IPEX: immunodysregulation 
polyendocrinopathy enteropathy X-linked syndrome [2].  
 
Chronic granulomatous disease 
DADA2 (Deficiency adenosine deaminase-2) 
HOIL-1 (Immunodeficiency, autoinflammatory, amylopectinosis) 
ISG15 (Interferon stimulant protein 15) deficiency 
APLAID (Autoinflammation and PLCᵧ2 associated antibody deficiency and immune 
dysregulation) 
Monogenic Autoinflammatory Diseases 
FMF, CAPS, TRAPS, PAPA, DITRA, DIRA, HIDS, BLAU, PRAAS, PAAND 
 
Mixed Pattern Diseases with MHC Class 1 association and 
autoinflammatory components 
Behcet’s Disease, Sarcoidosis, Sponyloarthritis Disease 
 
Classic Polygenetic Autoimmune Diseases (MHC Class 2 associated) 
RA, Addison’s disease, scleroderma, systemic lupus erythematous, type 1 
diabetes mellitus, Primary Biliary Cirrhosis, dermatomyositis, polymyositis, 
ANCA associated vasculitis, myasthenia gravis, autoimmune thyroid diseases, 
Coeliac Disease, vitiligo, pemphigus, pemphigoid 
 
Monogenic Autoimmune Diseases 
IPEX, APS1/APECD, ALPS 
Common variable immune deficiency (CVID) 
Deficiency recombinate activating genes 1 and 2 (RAG1/2) 
CTLA-4 haplodeficiency  
  IMMUNODEFICIENCY 
AUTOINFLAMMATION 
AUTOINFLAMMATION 
 IMMUNODEFICIENCY 
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released as the innate immune system activated 
are interleukin-1 (IL-1), IL-8, tumor necrosis 
factor alpha (TNFα) and type 1 interferons 
(IFNα and IFNβ). 
 
Inflammasome 
It is the signaling complex that provides the 
intracellular response of the innate immune 
system which was first described in 2002. Some 
cytosolic receptors in inflammasome formation 
include absent in melanoma-2 (AIM2), 
recombinant activation gene-1 (RAG-1), pyrin 
and most importantly NOD like receptor family 
(NLR) which includes NLRP3. It is 
schematized in Figure-2 [4].  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Inflammasome related cytoplasmic 
receptors [4].  
 
In the stimulation of cytosolic receptors, 
apoptosis-associated speck-like protein-
containing CARD (ASC) plays a role, acting as 
an adapter protein, cooperating in all 
inflammasomes. This step is organized by the 
inflammasome complex. It converts 
Procaspase-1, to the active form caspase-1 and 
stimulates the proinflammatory cytokines (pro-
IL-1β and pro-IL-18) to turn into their active 
forms. There are several factors that stimulate 
both endogenous and exogenous 
inflammasomes. An example of exogenous 
stimulants is pathogen-related molecular 
patterns (PAMPs). Lipopolysaccharides in 
gram-negative bacteria cell wall, lipoteichoic 
acid in gram-positive bacteria, double-stranded 
RNA viruses, peptidoglycan, flagellin are some 
of the PAMPs. Endogenous factors include 
nucleus and cytosolic proteins, that occurred 
during cell-death and damage-associated 
molecular patterns (DAMPS), which reacts to 
potential cancer cells and remove cellular 
residues [3]. Activation of inflammasome is 
critical for the innate immune system, and 
genetic mutations at this stage cause 
uncontrolled activations, leading to 
autoinflammatory diseases. 
 
Interleukin -1β (IL ‑ 1β) and IL ‑ 18 
IL-1β was detected before the identification of 
inflammasome. It is an acute phase reactant and 
a pyrogen. It is released from macrophages, 
dentritic cells, neutrophils and keratinocytes. It 
is activated by the IL-1 receptor type I (IL-1R) 
and stimulates the nuclear factor kappa light-
chain-enhancer of activate B cell (NFκB) and 
causes expression of cyclooxygenase-2. It also 
provides the release of IL-6 and TNF-α and 
cause fever. Under normal conditions, it is 
released during infections and initiates 
inflammation against the pathogens. 
Pathologically excessive stimulation or 
formation causes autoinflammation. Effects of 
IL-1α plays a role via IL-1R in healthy 
individuals and has a very low importance in 
autoinflammation [6]. In contrast, inhibitory 
drugs developed against IL-1β provided an 
important clinical response in the treatment of 
autoinflammatory diseases [7]. 
Information on IL-18 is less than IL-1β. It plays 
a role as IFN-γ and proinflammatory cytokines. 
Its role in fever formation and as an acute phase 
reactant is weak. It has a role in inflammatory  
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Monogenic autoinflammatory 
conditions 
Gene (protein) Clinic Manifestations  Treatment 
Familial Mediterranean fever 
(FMF) 
MEFV (pyrin) Fever, abdominal pain, arthritis, 
erysipelas-like skin rashes 
Colchicine, canakinumab, 
anakinra, rilonacept, 
TNF inhibitors 
Cryoporin-associated periodic 
syndromes (CAPS) 
NLRP3 (cryoporin) Fever, conjunctivitis, arthritis, 
urticaria  
Anakinra, rilonacept, 
canakinumab, steroid, 
NSAIDs 
Mevalonate kinase deficiency 
(MKD) 
MVK (mevalonate kinase) Fever, severe abdominal pain, 
diarrhea, arthralgia, rash, 
lymphadenopathy, 
splenomegaly,  
Corticosteroids, NSAIDs, 
anakinra, canakinumab, 
TNF inhibitors 
Tumor necrosis factor receptor-
associated periodic syndrome 
(TRAPS) 
TNFRSF1A (TNF receptor 
type 1) 
Fever, myalgia, abdominal pain, 
conjunctivitis 
Corticosteroids, NSAIDs, 
canakinumab, anakinra, 
etanercept 
Pyogenic arthritis, pyoderma 
gangrenosum, and acne (PAPA) 
syndrome 
PSTPIP1 
(proline/serine/threonine/ 
phosphatase-interacting 
protein) 
Erosive arthritis, pyoderma 
gangrenosum, acne 
Corticosteroids, anakinra, 
canakinumab, infliximab, 
adalimumab 
Pyrin-associated 
autoinflammation with 
neutrophilic dermatosis 
(PAAND) 
MEFV (pyrin) Fever, arthralgia, myositis, 
neutrophilic dermatosis 
Anakinra, infliximab, 
adalimumab 
Blau’s syndrome (familial 
juvenile systemic 
granulomatosis) 
NOD2 (nucleotide-binding 
oligomerization 
domain-containing protein 2) 
granulomatous reactions, 
tenosynovitis, uveitis 
Corticosteroids, 
methotrexate, cyclosporin, 
TNF inhibitors, anakinra 
Deficiency of the IL-1 receptor 
antagonist (DIRA) 
IL1RN (IL-1 receptor 
antagonist) 
Osteomyelitis, osteopenia, 
periostitis, pustular dermatitis 
Anakinra, canakinumab, 
rilonacept 
Deficiency of the IL-36 receptor 
antagonist (DITRA) 
IL36RN (IL-36 receptor 
antagonist) 
Fever, neutrophilia, pustular 
psoriasis 
Acitretin, corticosteroids, 
TNF inhibitors, 
methotrexate, cyclosporine, 
phototherapy 
Chronic atypical neutrophilic 
dermatosis with lipodystrophy 
and elevated temperature 
(CANDLE) syndrome 
lipodystrophy and elevated 
temperature 
(CANDLE) syndrome 
PSMA3, PSMB4, PSMB8, 
PSMB9 (proteasome 
subunits) 
Fever, progressive facial 
lipodystrophy, periorbital edema 
JAK inhibition with 
baricitinib, methotrexate, 
corticosteroids, 
cyclosporine, azathioprine, 
IVIG 
STING-associated 
vasculopathy with onset in 
infancy (SAVI) 
TMEM173 (STING) Acral vasculitis increasing 
with cold, pustular lesions 
Baricitinib, tofacitinib, 
ruxolitinib, corticosteroid 
 
Table 1. Monogenetic autoinflammatory diseases [10]. 
 
IL: Interleukin, IVIG: Intravenous immunoglobulin, JAK: Janus Kinase NSAIDs: Nonsteroidal anti-inflammatory drug; 
STING: Stimulator of interferon gene; TNF: Tumor necrosis factor.  
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Multifactorial 
autoinflammatory C Genes Clinic Manifestation Treatment 
Hidradenitis suppurativa (HS) 
  
Unknown Nodules with ulceration, abscesses, and 
fistulas; evolve into hypertrophic scars 
Adalimumab, infliximab, ustekinumab, 
anakinra, antibiotics, corticosteroids 
Generalized pustular psoriasis 
(GPP) 
  
CARD14, IL36RN Widespread subcorneal pustules 
overlying erythematous plaques 
Retinoids, cyclosporine, methotrexate, 
infliximab, gevokizumab, canakinumab, IL-
17A inhibitors 
Palmoplantar pustular 
psoriasis (PPPP) 
  
CARD14 Sterile pustules on palms and soles; 
hyperkeratosis and fissuring 
PUVA, UVB, acitretin, methotrexate, 
corticosteroids, cyclosporine, ustekinumab 
Synovitis, acne, pustulosis, 
hyperostosis, and osteitis 
(SAPHO) 
  
PSTPIP2, LPIN2, 
NOD2, IL1RN, 
unknown 
Osteomyelitis, hyperostosis, synovitis, 
acne, fissure 
  
NSAIDs, methotrexate, sulfasalazine, 
bisphosphonates, TNF inhibitors, 
ustekinumab, secukinumab, anakinra 
Pyoderma gangrenosum, acne, 
and suppurative hidradenitis 
(PASH) 
PSTPIP1, NLRP3, 
MEFV, NOD2, PSMB8, 
NCSTN 
Suppurative hidradenitis; acne; 
pyoderma gangrenosum later 
Anakinra, infliximab, adalimumab 
Behcet’s disease (BD) MEFV, HLA-B51, 
TNFAIP3, complex 
Oral aphthous ulcers; genital ulcers; 
erythema nodosum, vasculitis 
Colchicine, corticosteroids, azathioprine, 
thalidomide, cyclosporine, anakinra, 
cyclophosphamide, TNF inhibitors, 
canakinumab, tocilizumab 
Systemic juvenile idiopathic 
arthritis (SJIA) 
Complex Maculopapular rash,  
arthritis, fever, serositis, 
hepatosplenomegaly   
Corticosteroids, NSAIDs, canakinumab, 
anakinra, tocilizumab 
Adult-onset Still’s disease 
(AOSD) 
Complex Maculopapular rash,  
arthritis, fever, serositis, 
hepatosplenomegaly   
Corticosteroids, DMARDs, TNF inhibitors, 
anakinra, canakinumab, tocilizumab 
Schnitzler’s syndrome Unknown Urticarial-like lesions with neutrophilic 
infiltrates, fever, arthritis, IgM  
gammopathy 
Corticosteroids, anakinra, canakinumab, 
rilonacept 
Sweet’s syndrome (acute 
febrile neutrophilic 
dermatosis) 
HLA-B54, PTPN6, 
IDH1, MEFV, unknown 
Erythematous papules, nodules, and 
plaques, fever, leukocytosis 
Corticosteroids, colchicine, dapsone, 
potassium iodide, anakinra, TNF inhibitors 
Pyoderma gangrenosum (PG) 
  
  
MEFV, NLRP3, 
NLRP12, NOD2, 
LPIN2, PSTPIP1, JAK2, 
MTHFR, complex. 
Sterile pustules evolve into ulcers with 
undermined borders 
Corticosteroids, antibiotics, IVIG, 
thalidomide, infliximab, ustekinumab, 
canakinumab, anakinra 
Psoriasis 
  
CARD14, IL36RN, 
TNFAIP3, TNIP1, 
unknown 
Papules and plaques with silver scale, 
typically on extensor surfaces; sterile 
pustules; hyperkeratosis 
Corticosteroids, retinoids, phototherapy, 
methotrexate, cyclosporine, TNF inhibitors, 
ustekinumab, secukinumab, ixekizumab, 
apremilast 
Acne vulgaris 
  
Complex Comedones; papules; pustules; nodules; 
cysts 
Antibiotics, retinoids, salicylic acid, 
spironolactone, nitric oxide-releasing . 
Table 2. Multifactorial autoinflammatory diseases [10].  
DMARD: disease-modifying antirheumatic drug;IL: interleukin; IVIG: intravenous immunoglobulin; NSAIDs: nonsteroidal anti-
infammatory drug; PUVA: psoralen and ultraviyolet- A; Anti-TNF:tumor necrosis factor inhibitör drug;UVB: ultraviyolet B; IgM: 
immunoglobulin M gamopathy. 
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bowel disease, heart disease, metabolic 
syndrome and malignancy. In mouse studies 
with malignant melanomas, IL-18 inhibition 
has been shown to reduce the development of 
vascular cell adhesion molecule-1 (VCAM-1), 
reducing the development of metastasis [8]. 
Thus, IL-18 inhibition strategies are targeted in 
both inflammatory diseases and cancer 
treatment. 
 
Proteasome immunoproteasome 
In some patient groups, the absence of clinical 
response with IL-1 inhibitory therapy and 
continued studies investigating the 
pathogenesis of the disease led to the 
identification of proteasome-
immunoproteasome components. Proteasome-
immunoproteasomes are several multiprotein 
structures that are responsible for the removal 
of intracellular and foreign cell waste. After 
recognition of the Type-1 IFN receptor by the 
cell surface, Janus Kinase (JAK) and the 
transluser and activator transcription factor 
(STAT) are stimulated. These all together cause 
increased production of IFN, formation of cell 
damage associated oxygen radicals and 
nitrogen proteins. These proteins are cleared 
from the cell by proteasomes and immune 
proteasomes in sake of cell survival [9]. 
Autoinflammatory diseases are divided into 
two either as monogenic autoinflammatory 
diseases or multifactorial autoinflammatory 
diseases, according to the detected genetic 
mutations. In monogenetic diseases, a single 
gene region has been associated with the 
disease while in multifactorial diseases, many 
gene mutations have been associated with the 
disease. Table-1 presents monogenetic 
autoinflammatory diseases and associated gene 
mutations and Table-2 presents multifactorial 
autoinflammatory diseases and related gene 
mutations [10]. 
Behcet’s disease 
Behcet's disease (BD) is included in the 
multifactorial autoinflammatory diseases 
group. Common clinical signs of 
autoinflammatory diseases include; oral 
aphthae, arthritis, papulopustular skin lesions, 
pathergy test positivity, uveitis, 
meningoencephalitis, genital aphthae, 
epididymoorchitis, lymphadenopathy and 
amyloidosis. Since the clinical findings of BH 
are similar to the clinical findings of 
autoinflammatory diseases, studies have been 
conducted on this subject, considering that BH 
could be an autoinflammatory disease. In table-
3, the findings of BH that overlap with the clinic 
of autoinflammatory diseases are schematized 
[11]. 
 
Table 3. Clinical findings of Behcet’s disease that 
overlap with autoinflammatory diseases [11].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FMF: Familial Mediterranean fever; TRAPS: Tumor 
Necrosis Factor Receptor Associated Periodic 
Syndrome; CAPS: Cryopyrin-associated periodic 
syndrome; PAPA: Pyogenic Arthritis, Pyoderma 
Gangrenosum, Acne; DIRA: Deficiency of the 
interleukin-1–receptor antagonist; MKD: Mevalonate 
kinase deficiency. 
Behcet’s Disease’s  
Clinic Finding 
Autoinflammatory Diseases 
Oral aphthous  ulcers MKD,TRAPS,CAPS 
Skin pathergy reaction PAPA 
Arthritis FMF,TRAPS, PAPA, Blau’s 
Syndrome, CAPS, MKD 
Papulopustuler/acne like 
lesions 
DIRA, PAPA 
Meningoencephalitis FMF,CAPS 
Uveitis CAPS,TRAPS, Blau Syndrome 
Genital aphthous ulcers MKD 
Orchyepididymitis FMF 
Amyloidosis All autoinflammatory diseases 
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Pathogenesis of Behcet’s disease 
The over-activated natural immune response in 
BD triggers the release of T helper-1 and T cell 
17 (Th17). Natural immune system cells are 
predominated in the early stage of the 
pathological findings of the disease [12]. 
Neutrophilic vasculitis is a well-established 
pathological finding in BD. Changes in T cell 
balance are in favor of an increase in Th1 / Th17 
and a decrease in T regulator cell (Treg). 
Increased Th17 causes elevation of IL-17, IL-
23 and IFN- γ. Increased neutrophil infiltration 
develops as this pathway becomes active [13]. 
Pathologies associated with BH are 
schematized in Figure-3 and 4 [14]. 
 
 
 
 
 
 
 
 
 
 
Figure 3. Immunopathology related to innate immune 
system in Behçet's disease (MC: Macrophages; DC: 
Dentritic cell; CD8: CD8 T cell; NK: Natural killer 
cell) [14]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Immunopathology related to adaptive 
immune system in Behcet’s Disease (DC: Dentritic 
cell; CD8: CD8 cytotoxic T cell; Th1:T helper1cell; 
Th2: Thelper2 cell; Treg: T regulatory cell; Th17:T 17 
cell; PNL: neutrophils) [14]. 
On the other hand, there are studies showing 
that some microorganisms contribute to disease 
in susceptible individuals. Some streptococcal 
derivatives such as Streptococcus sanguinis,  
herpes simplex type-1 cause cross-reaction by 
showing homologous structure with human 
heat shock proteins (HSP) and have been shown 
to activate the immune system [15]. BH has 
been associated with microorganisms such as 
Borrelia burgdorferi, Helicobacter pylori, 
Cytomegalovirus, Epstein Barr virus, 
parvovirus, varicella zoster, but their 
relationship is unclear since these publications 
are consisted of few cases. Nevertheless, the 
role of microorganisms in disease pathogenesis 
is thought to be in the form of exacerbation of 
the disease [13,14]. 
 
Gene studies in Behcet’s disease     
Genetic studies conducted to elucidate Behcet’s 
disease pathogenesis showed the presence of 
gene mutations associated with the natural 
immune system in this condition. Genetic 
mutation studies detected in BD are presented 
in Table 4 [14]. MEFV gene mutations are 
mutations detected in FMF patients and have 
also been detected in BD. However, the 
relationship of MEFV gene mutation with 
Behcet’s Disease is not clear [16].   
The genome region encoding IL10 is the first 
gene region detected in BD. Although different 
missense variants in this gene region differ 
among communities, some variants have been 
shown to be associated with BD [14]. These 
variations have been associated with the 
formation of autoinflammation by decreasing 
the release of IL-10 from macrophages and not 
showing the effect of IL-10 in limiting 
inflammation. There are studies showing that 
IL-10 level is lower in BD than healthy 
individuals [17]. 
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Li et al. detected TNFAIP3 mutation in patients 
with 722 BH [18]. TNFAIP3 is the region 
encoding the ubiquitin modified enzyme A20. 
It plays an important regulatory role in the NF-
kB signaling pathway and provides TNF, toll 
like receptors (TLRs), IL-1R and NOD2 
release. 
The p.Arg725Gln, variant gene in the ERAP1 
gene    has     been    studied and detected in the  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Turkish population, and found to be higher in 
patients with positive HLA B51 allele [19]. The 
fact that the disease is seen more in some 
geographical regions suggested that this variant 
may be due to mutations. ERAP1 encodes 
aminopeptidase-1 in the endoplasmic reticulum 
and contributes to the production of the N-
terminal peptide suitable for antigen binding for 
the MHCclass-1 of the proteasome. 
Variant Gene Location Function of the risk allele 
rs1495965  IL23R,IL12RB2 Intergenic   
rs924080 IL23R,IL12RB2 Intergenic  
rs1518111 IL10 Intron Reduces expression in monocytes 
rs1800871 IL10 Promoter   
rs9494885 TNFAIP3 Intergenic No difference in expression in PBMCs 
rs7574070 STAT4 Intron Increases expression 
rs897200 STAT4 Intergenic Increases expression of STAT4 and IL17 
rs7616215 CCR1 Intergenic Decreases expression in monocytes, reduces monocyte 
chemotaxis 
rs13092160 CCR1, CCR3 Intergenic Decreases expression in PBMCs 
rs2617170 KLRC4 Missense   
M694V MEFV Missense Increases response to LPS 
rs17482078 ERAP1 Missense   
rs681343 FUT2 Synonymous   
rs17810546 IL12A Intergenic   
R381Q,G149R IL23R Missense Reduces IL-23 dependent IL-17 
D299G, T399I TLR4 Missense Reduces response to LPS, hyporesponsiveness to 
endotoxin 
R702W, G908R 
L1007fs 
NOD2 Missense 
Frame shift 
Reduces response to MDP 
 
Table 4. Gene studies of Behcet’s disease [14]. 
PBMC: Peripheral blood mononuclear cell; LPS: lipopolysaccharide; MDP: muramyl dipeptide. 
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Missense variant gene rs2617170 was detected 
in KLRC4 in the Turkish and Japanese 
population. This variation is related to the 
natural killer (NK) cell gene complex region. 
This variation was found in 23 of 83 BD 
patients. It is thought to cause 
autoinflammation by causing a 
communication-related pathology between the 
NK cell and the MHC gene [20]. However, the 
effect of these variations is still unclear. 
The intergenic region between IL23R-
IL12RB2 detected in BD is thought to cause 
increased expression of IL23R. IL23R is 
expressed in TH17 and macrophages [21]. 
Intergenetic and intron gene regions have been 
detected in STAT4-related gene regions. 
STAT4 causes IL12 and IL23 secretion and 
Naive T cell to transform into Th1 and Th17 
[22]. 
Genetic studies associated with FUT2 have 
suggested that it may be associated with disease 
exacerbation by affecting intestinal bacterial 
flora in BD [23]. 
On the other hand, Behcet’s Disease has a 
strong relationship with HLA-B51, and its 
degree of relationship has been found at 
different rates in different populations [24]. 
Some variant genes have also been shown to be 
associated with BD, albeit weak, at the HLA-A 
locus [25,26]. Ombrello et al. detected 16 
variants of HLA B mature protein amino acid 
sequence in BD patients by performing HLA 
Class 1 gene analysis with the Genome wide 
association studies (GWAS) method. This 
variation has been shown to cover antigen-
binding protein regions in MHC Class-1. It 
includes the antigen-binding protein region in 
variations detected at the HLA-A locus. It has 
been supported that these variations may lead to 
a pathology in the MHC Class 1 binding site, 
causing a problem in cytotoxic T cell or natural 
killer cell (NK) communication and causing 
inflammation [27]. In another study, the 
variation in amino acid sequence has shown 
that the communication between HLA-B and 
NKIR and KIR3DL1 / KIR3DS1 associated 
with cytotoxic T cell regulation is affected [28]. 
Also, ERAP1 affects cytotoxic T cell and NK 
cell communication with MHC Class1. Gene 
defects associated with ERAP1 were also 
detected in Behcet’s disease. Recent studies 
have focused on ERAP1 [29,30]. With all these 
results, the disease is thought to occur due to 
defect in MHC Class-1 and NK cell and 
cytotoxic T cell communication 
 
Conclusion 
Gene studies, pathological data, and cytokines 
related to Behcet’s disease pathogenesis show 
that the disease may have developed due to 
defects in multiple immune pathways. 
However, the natural immune system is an 
important step. With GWAS gene studies, it is 
thought that more progress will be made on the 
etiopathogenesis of the disease. 
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